HealthTech firm Medopad expands to the US following $28m raise

New York US

UK HealthTech company Medopad, which recently raised $28m at first close of its Series A, is expanding to the US.

The firm leverages AI as part of its data-capture platform offering and seeks to connect patients with healthcare professionals in what it says is real-time.

Medopad will be taking up an office in New York in Johnson & Johnson’s JLABS.

Dan Vahdat, CEO of Medopad, said: “We are thrilled to open a base in the USA as part of Johnson & Johnson’s incubator platform JLABS. This is a fantastic opportunity for Medopad as our values and vision are aligned with J&J’s leadership to help create a world where people can live longer. We value this partnership are looking forward to moving into our new office”.

“We have been working in partnership with US pharmaceuticals, healthcare providers and academic institutions such as Johns Hopkins where Medopad is used to connect clinicians to patients remotely and collect real world evidence. We look forward to strengthening these bonds and driving more innovative change for better health outcomes for people. The remote patient monitoring market is more than 8 times bigger in the US vs UK.”

Earlier this year, Medopad joined “Plug and Play”, a programme focused on business development,  in California.

Vahdat added: “The healthcare industry is highly-regulated and deeply complex, change is slower than is needed. Our disruptive healthcare patient monitoring solution will help bring great ideas from bench to bedside.”

Medopad is backed by investors including China’s NWS Holdings.